由于胰腺癌（PC）高度恶性，患者往往在早期就发展出转移，并对常规化疗显示出糟糕的反应。根据当前指南，PC的一线化疗方案包括氟嘧啶和吉西他滨。不断积累的药物耐受性研究表明，PC中的生化代谢异常，特别是涉及糖酵解和谷氨酰胺代谢的异常，与耐药性密切相关。此外，脂质代谢是化疗耐药的主要因素。然而，以这些关键代谢途径为靶点的新化合物有潜力克服化疗耐药性。本综述总结了PC如何通过生化代谢异常发展化疗耐药性，并讨论了癌症代谢中新药研究的关键靶点和途径。版权属于2023年中国医师协会，由Wolters Kluwer，Inc.根据CC-BY-NC-ND许可证制作。

As pancreatic cancer (PC) is highly malignant, its patients tend to develop metastasis at an early stage and show a poor response to conventional chemotherapies. First-line chemotherapies for PC, according to current guidelines, include fluoropyrimidine- and gemcitabine-based regimens. Accumulating research on drug resistance has shown that biochemical metabolic aberrations in PC, especially those involving glycolysis and glutamine metabolism, are highly associated with chemoresistance. Additionally, lipid metabolism is a major factor in chemoresistance. However, emerging compounds that target these key metabolic pathways have the potential to overcome chemoresistance. This review summarizes how PC develops chemoresistance through aberrations in biochemical metabolism and discusses novel critical targets and pathways within cancer metabolism for new drug research.Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.